We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
TGen-VARI-SHC Research Helps Predict Success with Cancer Drugs
News

TGen-VARI-SHC Research Helps Predict Success with Cancer Drugs

TGen-VARI-SHC Research Helps Predict Success with Cancer Drugs
News

TGen-VARI-SHC Research Helps Predict Success with Cancer Drugs

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "TGen-VARI-SHC Research Helps Predict Success with Cancer Drugs"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Researchers at the Translational Genomics Research Institute (TGen), the Van Andel Research Institute (VARI) and the Virginia G. Piper Cancer Center at Scottsdale Healthcare have discovered a biomarker that could help in the treatment of patients with an aggressive type of lung cancer.

Using a particular biomarker, researchers might better predict which patients with small cell lung cancer are resistant to existing drug therapies, and which ones could benefit from new therapies tailored to their specific needs, according to a scientific paper published in the Journal of Thoracic Oncology.

“There is a need for predictive biomarkers that can aid investigators in designing future clinical trials, to help identify treatments that might be effective for these patients who most likely will be resistance to existing drug therapies,” said Dr. Glen J. Weiss, the paper’s senior author and Director of Thoracic Oncology at TGen Clinical Research Services at Scottsdale Healthcare.

TCRS is a partnership between TGen and Scottsdale Healthcare that helps bring new therapies quickly to patients at the Virginia G. Piper Cancer Center in Scottsdale.

Researchers from TGen, VARI and the Virginia G. Piper Cancer Center at Scottsdale Healthcare focused on identifying microRNAs, which are single-stranded RNA molecules that regulate how genes and proteins control cellular development. Because microRNAs are so resilient, they are relatively easy to detect in tumor tissue and blood, which is often a limitation for other biomarkers.

"VARI provided bioinformatics support assembling all the different types of data into a cohesive data set for analysis to help identify the miRNA that play a role in the survival of the lung cancer patients," said Dr. David Cherba, a VARI Bioinformatics Scientist.

Researchers profiled 34 tumor samples from patients with a median age of 69. They analyzed each tumor’s microRNAs, searching for those that might be associated with cancer survival.

They identified three microRNAs associated with SCLC. But one in particular, identified as miR-92a-2*, was “significantly” linked to survival, the paper said.

“Our results demonstrate that higher tumor miR-92a-2* levels are associated with chemoresistance and with decreased survival in SCLC patients,” said the paper titled MicroRNA 92a-2*, a Biomarker Predictive for Chemoresistance and Prognostic for Survival in Small Cell Lung Cancer Patients.

This was one of the first scientific papers published since the completion of the TGen-VARI alliance and affiliation agreement, announced in February.

"The collaboration that occurred on this project highlights the synergies created by the VARI-TGen alliance," said Dr. Craig Webb, a VARI Senior Scientific Investigator.

Dr. Jeffrey Trent, President and Research Director for TGen and VARI, said the new discoveries could have profound implications for the future of medicine.

“This advanced technology is exciting because of how these microRNA biomarkers could lead to improvements for patients. Hopefully, this will translate to new treatments and improved survival,” Dr. Trent said.

Advertisement